While the endogenous opioid system has generally been associated with regulation of pain, it also modulates the experience of distress and may play a central role in many psychiatric and neurodevelopmental disorders. ...While the endogenous opioid system has generally been associated with regulation of pain, it also modulates the experience of distress and may play a central role in many psychiatric and neurodevelopmental disorders. Decades of preclinical research on the analgesic effects of endogenous opioids, i.e., endorphins, suggests that opioid receptors have plastic bimodal (inhibitory/excitatory) properties that may explain conflicting findings in clinical research. An exploratory study with 60 healthy volunteer participants, using a cold pressor-induced pain paradigm, found evidence that a combination of a nutraceutical agent that enhances endorphin release (Endorphin Enhancer) with one that switches opioid receptors from an excitatory to inhibitory mode (Opioid Receptor Switcher) not only increases pain tolerance but also reduces emotional and physical distress. This discovery led to clinical application of a critically formulated endorphinergic treatment in 203 case studies over a two-year period. Findings revealed the remarkable clinical efficacy and safety of this treatment in the relief of chronic emotional and physical distress, including anxiety, anger, depression, cravings, and hyperalgesia, as well as enhancement of well-being, productivity, mental clarity, relationships, and an adaptive response to life’s stresses. These studies provide new insights into the role of endogenous opioid system imbalances in the development, treatment, and prevention of dysfunctional emotional and physical distress. We postulate that an Endorphinergic Distress Syndrome (EDS) consists of abnormal endorphin levels together with opioid receptors predominately in their excitatory mode. EDS may account for many core distress symptoms associated with chronic anxiety, addictions, pain, as well as affective personality, autism spectrum, attention-deficit, and distress-related medical problems. Our research has led to new endorphinergic formulations, combining Endorphin Enhancers, such as caffeine, with Opioid Receptor Switchers, such as n-acetylcysteine, for the relief of emotional and physical distress. Our studies also provide a novel method to reverse the anxiogenic effects of caffeine and related hyperexcitatory substances.展开更多
The endogenous opioid system plays a significant role in the modulation of distress in many psychiatric, neurologic, and neurodevelopmental disorders. Many clinical distress symptoms show similarities to the excitator...The endogenous opioid system plays a significant role in the modulation of distress in many psychiatric, neurologic, and neurodevelopmental disorders. Many clinical distress symptoms show similarities to the excitatory autonomic withdrawal effects in chronic opioid-dependent animals and humans, as well as to the “quasi-morphine withdrawal syndrome” evoked in naive rodents shortly after acute systemic injection of cyclic AMP-phosphodiesterase (cAMP-PDE) inhibitors. These symptoms result from excessive excitatory opioid receptor signaling and increased endorphin release. Pharmacologic analyses of the remarkably plastic bimodal (excitatory/inhibitory) signaling functions of opioid receptors have utilized microelectrode recordings from opioid-sensitive neurons in tissue cultures of mouse sensory ganglia and hot-water tail-flick assays in mice. These studies led to development of specific chemical formulations that switch opioid receptor signaling from an excessively excitatory to a normal inhibitory mode. Critical combinations of cAMP-PDE inhibitors that release endorphins plus specific agents that switch opioid receptors from excitatory Gs-coupled to inhibitory Gi/Go-coupled signaling were shown to attenuate hyperalgesia and distress evoked by diverse chemical stressors in mouse tail-flick assays. Both the “quasi-morphine withdrawal syndrome” in naive rodents as well as the excitatory withdrawal effects in chronic, opioid-dependent animals and humans may be manifestations of a common Endorphinergic Distress Syndrome (EDS). We suggest that many distress symptoms are caused by EDS, a dysfunctional imbalance in the endogenous opioid system, consisting of abnormal endorphin levels, together with opioid receptors predominately in their excitatory mode. Therefore, concomitantly enhancing endogenous opioid release and switching excessive excitatory opioid receptor signaling to inhibitory signaling can attenuate these distress symptoms. Trials of a critically formulated oral preparation, containing both endorphin enhancers and opioid receptor switchers, have resulted in long-term anxiolytic efficacy and enhanced calm and mental clarity in large numbers of individuals with distress symptoms. These endorphinergic formulations may provide treatment for the emotional and physical distress associated with many psychiatric, neurologic, and neurodevelopmental disorders.展开更多
目的:探讨小鼠疼痛模型的昼夜节律和注射用蜂毒(Bee venom for injection,BVI)镇痛作用的昼夜差异及其相关机制。方法:采用热板法、辐射热甩尾法建立小鼠疼痛模型,在6个授时(Zeitgeber time,ZT)时间点(ZT2、ZT6、ZT10、ZT14、ZT18、ZT22...目的:探讨小鼠疼痛模型的昼夜节律和注射用蜂毒(Bee venom for injection,BVI)镇痛作用的昼夜差异及其相关机制。方法:采用热板法、辐射热甩尾法建立小鼠疼痛模型,在6个授时(Zeitgeber time,ZT)时间点(ZT2、ZT6、ZT10、ZT14、ZT18、ZT22)测量痛阈并分析其昼夜节律。将合格昆明小鼠随机分为注射用蜂毒大剂量(Bee venom for injection-High dose,BVI-H)、注射用蜂毒中剂量(Bee venom for injection-Medium dose,BVI-M)、注射用蜂毒低剂量(Bee venom for injection-low dose,BVI-L)、吗啡(Morphine,MOR)和模型(Model,MOD)组;每组再根据小鼠痛阈的昼夜节律分为两个亚组,分别在痛阈的峰值和谷值2个时间点给药。观察各组对热板法、辐射热甩尾法和扭体法疼痛模型小鼠行为学影响的动态变化;ELISA法检测血清P物质(Substances P,SP)、β-内啡肽(Beta-endorphin,β-EP)和IL-1β(interleukin-1β,IL-1β)水平。结果:小鼠疼痛模型的痛阈显示出峰值在明中期(ZT6)、谷值在暗后期(ZT22)的昼夜节律。BVI三个剂量组和MOR组均显示出明显的镇痛作用,并且BVI在热板法和扭体法模型的镇痛作用具有剂量依赖性。在热板法和辐射热法疼痛模型中,BVI于ZT22给药比ZT6给药显示出更强的镇痛作用。蜂毒对疼痛模型小鼠血清β-EP水平未显示上调作用;但可明显降低血清SP含量,且具有ZT22给药低于ZT6给药的昼夜变化(P<0.05);对扭体法和辐射热法(仅ZT22给药组)疼痛模型小鼠血清IL-1β水平显著下调,而在热板法则显示IL-1β水平明显增高。结论:小鼠的痛阈存在峰值在明中后期、谷值在暗后期的昼夜节律;BVI对小鼠多种疼痛模型均具有镇痛作用,且存在昼夜差异;BVI的镇痛作用及其昼夜变化可能与调节内源性疼痛介质有关。展开更多
AIM To study the role of cholecystokinin- octapeptide (CCK-8). β-endorphin (β-EP). and gastrin in an anorexic infantile rat model and no subsequent regulation of nose peptides by the Yunpi complex prescription Er...AIM To study the role of cholecystokinin- octapeptide (CCK-8). β-endorphin (β-EP). and gastrin in an anorexic infantile rat model and no subsequent regulation of nose peptides by the Yunpi complex prescription ErBao Granule. METHODS We fed infantile rats with special prepared forage. A liquid extract of ErBao Granule was administered to the rats daily for 3 weeks, CCK-8, β-EP, and gastrin concentrations in hypothalamus, gastric antrum, and plasma of the rats were measured by radioimmunoassay, and were compared with controls. RESULTS Treatment of rats with ErBao Granule inhibited CCK-8 secretion and increased β-EP and gastrin secretion. CCK-8 concentration in hypothalamus and plasma of model control group increased significantly and correlated negatively with food intake of models, respectively. β-EP concentration in gastric antrum and plasma of model control group decreased significantly and showed a positive correlation with food intake of models, respectively. Hypothalamus concentration of β -EP was similar in models and controls. Gastrin concentration in gastric antrum of models was lower than in the blank control group, and correlated positively to food intake of models. Finally, CCK-8 concentrations in plasma of rats showed a positive correlation with plasma β-EP (r=-0.68, P<0.05). CONCLUSION The increased plasma and hypothalamus concentration of CCK-8, decreased gastric antrum and plasma level of β -EP, and decreased gastric antrum concentration of gastric are associated significantly with the anorexia of infantile anorexic rat models produced by special forage. ErBao Granule can reverse these changes, which may be the major mechanisms of ErBao Granule simulating feeding.展开更多
文摘While the endogenous opioid system has generally been associated with regulation of pain, it also modulates the experience of distress and may play a central role in many psychiatric and neurodevelopmental disorders. Decades of preclinical research on the analgesic effects of endogenous opioids, i.e., endorphins, suggests that opioid receptors have plastic bimodal (inhibitory/excitatory) properties that may explain conflicting findings in clinical research. An exploratory study with 60 healthy volunteer participants, using a cold pressor-induced pain paradigm, found evidence that a combination of a nutraceutical agent that enhances endorphin release (Endorphin Enhancer) with one that switches opioid receptors from an excitatory to inhibitory mode (Opioid Receptor Switcher) not only increases pain tolerance but also reduces emotional and physical distress. This discovery led to clinical application of a critically formulated endorphinergic treatment in 203 case studies over a two-year period. Findings revealed the remarkable clinical efficacy and safety of this treatment in the relief of chronic emotional and physical distress, including anxiety, anger, depression, cravings, and hyperalgesia, as well as enhancement of well-being, productivity, mental clarity, relationships, and an adaptive response to life’s stresses. These studies provide new insights into the role of endogenous opioid system imbalances in the development, treatment, and prevention of dysfunctional emotional and physical distress. We postulate that an Endorphinergic Distress Syndrome (EDS) consists of abnormal endorphin levels together with opioid receptors predominately in their excitatory mode. EDS may account for many core distress symptoms associated with chronic anxiety, addictions, pain, as well as affective personality, autism spectrum, attention-deficit, and distress-related medical problems. Our research has led to new endorphinergic formulations, combining Endorphin Enhancers, such as caffeine, with Opioid Receptor Switchers, such as n-acetylcysteine, for the relief of emotional and physical distress. Our studies also provide a novel method to reverse the anxiogenic effects of caffeine and related hyperexcitatory substances.
文摘The endogenous opioid system plays a significant role in the modulation of distress in many psychiatric, neurologic, and neurodevelopmental disorders. Many clinical distress symptoms show similarities to the excitatory autonomic withdrawal effects in chronic opioid-dependent animals and humans, as well as to the “quasi-morphine withdrawal syndrome” evoked in naive rodents shortly after acute systemic injection of cyclic AMP-phosphodiesterase (cAMP-PDE) inhibitors. These symptoms result from excessive excitatory opioid receptor signaling and increased endorphin release. Pharmacologic analyses of the remarkably plastic bimodal (excitatory/inhibitory) signaling functions of opioid receptors have utilized microelectrode recordings from opioid-sensitive neurons in tissue cultures of mouse sensory ganglia and hot-water tail-flick assays in mice. These studies led to development of specific chemical formulations that switch opioid receptor signaling from an excessively excitatory to a normal inhibitory mode. Critical combinations of cAMP-PDE inhibitors that release endorphins plus specific agents that switch opioid receptors from excitatory Gs-coupled to inhibitory Gi/Go-coupled signaling were shown to attenuate hyperalgesia and distress evoked by diverse chemical stressors in mouse tail-flick assays. Both the “quasi-morphine withdrawal syndrome” in naive rodents as well as the excitatory withdrawal effects in chronic, opioid-dependent animals and humans may be manifestations of a common Endorphinergic Distress Syndrome (EDS). We suggest that many distress symptoms are caused by EDS, a dysfunctional imbalance in the endogenous opioid system, consisting of abnormal endorphin levels, together with opioid receptors predominately in their excitatory mode. Therefore, concomitantly enhancing endogenous opioid release and switching excessive excitatory opioid receptor signaling to inhibitory signaling can attenuate these distress symptoms. Trials of a critically formulated oral preparation, containing both endorphin enhancers and opioid receptor switchers, have resulted in long-term anxiolytic efficacy and enhanced calm and mental clarity in large numbers of individuals with distress symptoms. These endorphinergic formulations may provide treatment for the emotional and physical distress associated with many psychiatric, neurologic, and neurodevelopmental disorders.
文摘目的:探讨小鼠疼痛模型的昼夜节律和注射用蜂毒(Bee venom for injection,BVI)镇痛作用的昼夜差异及其相关机制。方法:采用热板法、辐射热甩尾法建立小鼠疼痛模型,在6个授时(Zeitgeber time,ZT)时间点(ZT2、ZT6、ZT10、ZT14、ZT18、ZT22)测量痛阈并分析其昼夜节律。将合格昆明小鼠随机分为注射用蜂毒大剂量(Bee venom for injection-High dose,BVI-H)、注射用蜂毒中剂量(Bee venom for injection-Medium dose,BVI-M)、注射用蜂毒低剂量(Bee venom for injection-low dose,BVI-L)、吗啡(Morphine,MOR)和模型(Model,MOD)组;每组再根据小鼠痛阈的昼夜节律分为两个亚组,分别在痛阈的峰值和谷值2个时间点给药。观察各组对热板法、辐射热甩尾法和扭体法疼痛模型小鼠行为学影响的动态变化;ELISA法检测血清P物质(Substances P,SP)、β-内啡肽(Beta-endorphin,β-EP)和IL-1β(interleukin-1β,IL-1β)水平。结果:小鼠疼痛模型的痛阈显示出峰值在明中期(ZT6)、谷值在暗后期(ZT22)的昼夜节律。BVI三个剂量组和MOR组均显示出明显的镇痛作用,并且BVI在热板法和扭体法模型的镇痛作用具有剂量依赖性。在热板法和辐射热法疼痛模型中,BVI于ZT22给药比ZT6给药显示出更强的镇痛作用。蜂毒对疼痛模型小鼠血清β-EP水平未显示上调作用;但可明显降低血清SP含量,且具有ZT22给药低于ZT6给药的昼夜变化(P<0.05);对扭体法和辐射热法(仅ZT22给药组)疼痛模型小鼠血清IL-1β水平显著下调,而在热板法则显示IL-1β水平明显增高。结论:小鼠的痛阈存在峰值在明中后期、谷值在暗后期的昼夜节律;BVI对小鼠多种疼痛模型均具有镇痛作用,且存在昼夜差异;BVI的镇痛作用及其昼夜变化可能与调节内源性疼痛介质有关。
基金Project supported by the National Natural Science Foundation of China,No.39670896
文摘AIM To study the role of cholecystokinin- octapeptide (CCK-8). β-endorphin (β-EP). and gastrin in an anorexic infantile rat model and no subsequent regulation of nose peptides by the Yunpi complex prescription ErBao Granule. METHODS We fed infantile rats with special prepared forage. A liquid extract of ErBao Granule was administered to the rats daily for 3 weeks, CCK-8, β-EP, and gastrin concentrations in hypothalamus, gastric antrum, and plasma of the rats were measured by radioimmunoassay, and were compared with controls. RESULTS Treatment of rats with ErBao Granule inhibited CCK-8 secretion and increased β-EP and gastrin secretion. CCK-8 concentration in hypothalamus and plasma of model control group increased significantly and correlated negatively with food intake of models, respectively. β-EP concentration in gastric antrum and plasma of model control group decreased significantly and showed a positive correlation with food intake of models, respectively. Hypothalamus concentration of β -EP was similar in models and controls. Gastrin concentration in gastric antrum of models was lower than in the blank control group, and correlated positively to food intake of models. Finally, CCK-8 concentrations in plasma of rats showed a positive correlation with plasma β-EP (r=-0.68, P<0.05). CONCLUSION The increased plasma and hypothalamus concentration of CCK-8, decreased gastric antrum and plasma level of β -EP, and decreased gastric antrum concentration of gastric are associated significantly with the anorexia of infantile anorexic rat models produced by special forage. ErBao Granule can reverse these changes, which may be the major mechanisms of ErBao Granule simulating feeding.
